GlassScriptPhysician profile
Mark S Pelikan
NPI 1891769253
$6,934.34
in general payments reported to CMS, 2019-2025
42 companies · $1,196 in 2025
The $1,196 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,316 · 2020: $605 · 2021: $759 · 2022: $867 · 2023: $1,110 · 2024: $1,081 · 2025: $1,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,387.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,305.31 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,071.40 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $797.48 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $632.63 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $558.65 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Sanofi-Aventis U.S. LLC | $283.56 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.79 | 2019-2025 | Jardiance |
| Amgen INC. | $174.11 | 2019-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $173.72 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $158.41 | 2020-2025 | Gardasil 9, Capvaxive |
| Phathom Pharmaceuticals, INC. | $137.66 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $129.96 | 2019-2020 | |
| Corcept Therapeutics | $111.85 | 2022-2023 | Korlym |
| Novartis Pharmaceuticals Corporation | $111.46 | 2019-2023 | |
| Medtronic, INC. | $103.94 | 2022 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $101.90 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $94.34 | 2019-2021 | |
| Abbott Laboratories | $92.55 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Ascendis Pharma Endocrinology INC | $82.17 | 2023-2025 | Skytrofa |
| Azurity Pharmaceuticals, INC. | $79.47 | 2024-2025 | Triptodur, Edarbi, Horizant |
| Tolmar, INC. | $77.95 | 2023-2025 | Fensolvi |
| Tris Pharma INC | $67.30 | 2019-2023 | Dyanavel Xr |
| Exact Sciences Corporation | $41.21 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amarin Pharma, INC. | $38.85 | 2019-2020 | |
| Insulet Corporation | $33.18 | 2019-2021 | |
| Allergan, INC. | $30.89 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.02 | 2020 | |
| Neurocrine Biosciences, INC. | $23.00 | 2025 | |
| Neurelis, INC. | $19.57 | 2023 | Valtoco |
| Eisai INC. | $18.70 | 2021 | |
| Grifols USA, LLC | $17.87 | 2025 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $16.15 | 2024 | |
| Lundbeck LLC | $15.45 | 2025 | Rexulti |
| Ultragenyx Pharmaceutical INC. | $15.35 | 2019 | |
| Ironshore Pharmaceuticals INC. | $14.77 | 2019 | |
| Recor Medical INC | $13.82 | 2024 | Paradise Renal Denervation System |
| Shire North American Group INC | $13.74 | 2019 | |
| Medtronic Minimed, INC. | $13.48 | 2020 | |
| Impel Pharmaceuticals INC. | $13.28 | 2023 | Trudhesa |
| Sanofi Pasteur INC. | $12.62 | 2019 | |
| Kaleo, INC. | $12.57 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Pelikan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.